Efficacy and safety of boosted darunavir-based antiretroviral therapy in HIV-1-positive patients: results from a meta-analysis of clinical trials

Short Communication: Efficacy and Safety of Treatment Simplification to Lopinavir/Ritonavir or Darunavir/Ritonavir Monotherapy: A Randomized Clinical Trial

(2016) José R. Santos et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Week 96 efficacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial

(2016) PM Girard et al.   HIV MEDICINE

HIV-1 drug resistance and resistance testing

(2016) Dana S. Clutter et al.   INFECTION GENETICS AND EVOLUTION

NRTI Sparing Therapy in Virologically Controlled HIV-1 Infected Subjects

(2016) Franco Maggiolo et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial)

(2016) Laurence Slama et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Week 48 efficacy and central nervous system analysis of darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues

(2015) Andrea Antinori et al.   AIDS

Effects on vitamin D, bone and the kidney of switching from fixed-dose tenofovir disoproxil fumarate/emtricitabine/efavirenz to darunavir/ritonavir monotherapy: a randomized, controlled trial (MIDAS)

(2015) Lisa Hamzah et al.   ANTIVIRAL THERAPY

Simplification from twice-daily to once-daily darunavir/ritonavir in a randomized trial among HIV-infected persons with HIV-1 RNA suppression on antiretroviral therapy

(2015) Gregory D Huhn et al.   ANTIVIRAL THERAPY

Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257

(2015) I. Ofotokun et al.   CLINICAL INFECTIOUS DISEASES

Darunavir/cobicistat for the treatment of HIV-1: a new era for compact drugs with high genetic barrier to resistance

(2015) Amedeo Capetti et al.   EXPERT OPINION ON PHARMACOTHERAPY

Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial

(2015) Antoine Chéret et al.   LANCET INFECTIOUS DISEASES

Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study

(2015) Jean-Michel Molina et al.   Lancet HIV

Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1

(2014) Jeffrey L. Lennox et al.   ANNALS OF INTERNAL MEDICINE

Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs in HIV-Infected Patients Are Associated With Compartmental Viral Control

(2014) Andrea Calcagno et al.   CLINICAL INFECTIOUS DISEASES

Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir

(2014) E Martinez et al.   HIV MEDICINE

Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

(2014) François Raffi et al.   LANCET

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

(2014) Bonaventura Clotet et al.   LANCET

Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues

(2014) Courtney V. Fletcher et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Darunavir: A Review of Its Use in the Management of HIV-1 Infection

(2013) Emma D. Deeks   DRUGS

Randomized Trial to Evaluate Cardiometabolic and Endothelial Function in Patients with Plasma HIV-1 RNA Suppression Switching to Darunavir/Ritonavir with or without Nucleoside Analogues

(2013) G. Guaraldi et al.   HIV CLINICAL TRIALS

A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction

(2013) J Baril et al.   HIV MEDICINE

Switching Tenofovir/Emtricitabine plus Lopinavir/r to Raltegravir plus Darunavir/r in Patients with Suppressed Viral Load Did Not Result in Improvement of Renal Function but Could Sustain Viral Suppression: A Randomized Multicenter Trial

(2013) Takeshi Nishijima et al.   PLoS One

Metabolic Effects of Darunavir/Ritonavir Versus Atazanavir/Ritonavir in Treatment-Naive, HIV Type 1-Infected Subjects over 48 Weeks

(2012) Judith A. Aberg et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Week 96 Efficacy, Virology and Safety of Darunavir/r Versus Lopinavir/r in Treatment-Experienced Patients in TITAN

(2012) Denes Banhegyi et al.   CURRENT HIV RESEARCH

Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial

(2012) C Orkin et al.   HIV MEDICINE

Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients

(2011) Pedro Cahn et al.   AIDS

Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis

(2011) Erkki Lathouwers et al.   ANTIVIRAL THERAPY

96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA

(2011) N. Clumeck et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48

(2009) Roberto Ortiz et al.   AIDS

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

(2009) Anthony M Mills et al.   AIDS

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml

(2009) Jose R Arribas et al.   AIDS

Effect of Baseline Viral Susceptibility on Response to Darunavir/Ritonavir versus Control Protease Inhibitors in Treatment-Experienced HIV Type 1-Infected Patients: POWER 1 and 2

(2008) Anton Pozniak et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES